Alnylam Pharmaceuticals welcomes Dr. Elliott Sigal to its Board of Directors

– USA, MA –  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, today announced the appointment of Dr. Elliott Sigal (M.D., Ph.D.) to its Board of Directors, bringing decades of senior leadership and board experience at biopharmaceutical companies.

“We are thrilled to welcome Elliott to our Board at an especially important and exciting time in our Company’s history. As a deeply accomplished leader, Elliott will bring valuable experience to Alnylam and our Board as we continue to advance our RNAi therapeutics to transform the lives of patients afflicted with rare and prevalent diseases with unmet need. We look forward to his contributions in the years ahead,” said CEO, Yvonne Greenstreet.

About Dr. Elliott Sigal

Dr. Elliott Sigal served as CSO and President of R&D for Bristol-Myers Squibb and as a director on the board. During his tenure at BMS, he was instrumental in building the company’s leading research position in immuno-oncology. Under his leadership, 14 new medicines came to market in multiple therapeutic areas, including cardiometabolic, infectious, inflammatory, neuroscience, and oncology.

“Alnylam has revolutionized RNAi as a new class of medicines that improve patients’ lives,” said Dr. Elliott Sigal. “I am excited to join the Company at this critical inflection point and to work with the Board and management as we continue to grow the company’s commercial portfolio and advance its RNAi therapeutic pipeline.”

Dr. Sigal currently serves as co-chair of the Scientific Advisory Board for Amgen, Inc. and as a senior advisor to the healthcare team of New Enterprise Associates. He is a member of the Board of Directors for the public biotechnology companies Adaptimmune Therapeutics plc, Vir Biotechnology, Inc., and Surface Oncology, Inc., as well as the private companies Tessera Therapeutics and Affinia Therapeutics Inc. Prior Board positions include Spark Therapeutics, Inc. from 2014 to 2019, Mead Johnson Nutrition from 2009 to 2017 and BMS from 2011 to 2013.

About Alnylam Pharmaceuticals

Alnylam has led the translation of RNA interference into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), AMVUTTRA (vutrisiran), and Leqvio (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients worldwide through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

For more information: https://www.alnylam.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.